Vergelijking

Histrelin vs. Icatibant

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

220810-26-4

138614-30-9

Molecuulmassa

1323.52 g/mol

1304.52 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Histrelin

Continuous GnRH-agonist stimulation downregulates and desensitises the pituitary GnRH receptors — after the initial rise, LH, FSH and the sex hormones fall persistently.

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Histrelin	Icatibant
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Histrelin

Volledige vermelding →

Icatibant

Volledige vermelding →

Frequently asked questions

What is the difference between Histrelin and Icatibant?: Histrelin is classified as "Onderzoek (overig)", while Icatibant is classified as "Onderzoek (overig)". Histrelin: Histrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas). Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Histrelin or Icatibant?: The highest available evidence level is "Humane RCT" for Histrelin and "Humane RCT" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Histrelin and Icatibant in Germany and the United States?: Duitsland: Histrelin — Op recept, Icatibant — Op recept. Verenigde Staten: Histrelin — Op recept, Icatibant — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Histrelin

Icatibant

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Histrelin and Icatibant?

Histrelin is classified as "Onderzoek (overig)", while Icatibant is classified as "Onderzoek (overig)". Histrelin: Histrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas). Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Histrelin or Icatibant?

The highest available evidence level is "Humane RCT" for Histrelin and "Humane RCT" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Histrelin and Icatibant in Germany and the United States?

Duitsland: Histrelin — Op recept, Icatibant — Op recept. Verenigde Staten: Histrelin — Op recept, Icatibant — Op recept. These are factual summaries with source and review date on the individual pages.